secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuo Therapeutics, Inc. (AURX)
CIK:        0001091596
Form:       8-K
Filed at:   2026-10-06T20:57:28+00:00
Accession:  0001437749-26-032242
Event type: debt
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Nuo Therapeutics closes $325,000 Second Funding, reaching $2,000,000 total loan funding
--------------------------------------------------------------------------------

- Nuo Therapeutics received the $325,000 Second Funding on October 6, 2026, bringing aggregate Lender funding under the Loan Agreement to $2,000,000.
- The Second Closing Date was moved from September 30 to October 6, 2026 via an Assignment, Joinder, and Amendment No. 1.
- Scott M. Pittman, a director and >10% beneficial owner, assumed $25,000 and received warrants for 4,500 shares, 458 prepayment shares, and up to 2,750 interest shares.
- Second Notes bear 12% annual interest, mature December 31, 2028, and Assuming Lenders received warrants for 18,000 shares plus 1,832 prepayment shares.
- Three new unaffiliated lenders joined, and four Assuming Lenders took the assigned $100,000 Second Funding commitment in equal $25,000 portions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1091596/000143774926032242/0001437749-26-032242-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1091596/000143774926032242/aurx20261006c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-032242

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer